

This is an update about information in the provider manual.
For access to the latest provider manual, go online to <https://providers.amerigroup.com>.

Continuous interstitial glucose monitoring to require prior authorization

Summary: Effective April 1, 2017, Amerigroup STAR+PLUS MMP (Medicare-Medicaid Plan) will require prior authorization (PA) for continuous interstitial glucose monitoring.

Noncompliance with new requirements may result in denied claims.

PA requirements will be added to the following codes:

- 95250: ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours — sensor placement, hook-up, calibration of monitor, patient training, removal of sensor and printout of recording
- 95251: ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours — interpretation and report

Federal and state law as well as state contract language and CMS guidelines, including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining coverage.

Not all PA requirements are listed here. For more information, go to <https://providers.amerigroup.com/TX> > Provider Resources & Documents > Quick Tools > Precertification Lookup Tool. You may also call Provider Services at 1-855-878-1785.